-
Sichuan Kelun-Biotech’s Ketailai Receives NMPA Approval for Nasopharyngeal Carcinoma Treatment
•
China-based Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd (HKG: 6990) has announced that it has received marketing approval from the National Medical Products Administration (NMPA) for its programmed death ligand 1 (PD-L1) monoclonal antibody (mAb), Ketailai (KL-A167). This treatment is now approved for use in recurrent or metastatic nasopharyngeal carcinoma (NPC) patients…
-
Sino Biopharmaceutical’s Chia Tai Tianqing Secures Exclusive Promotion Rights for Naldemedine in China
•
China-based Sino Biopharmaceutical Ltd (HKG: 1177) has announced an exclusive market promotion agreement between its subsidiary Chia Tai Tianqing and Ping An-Shionogi Co., Ltd, a joint venture between China-based commercial insurance firm Ping An Insurance (Group) Ltd and Japanese pharmaceutical firm Shionogi & Co., Ltd. Under this initially 11-year accord,…
-
HutchMed’s Orpathys Receives Priority Review for NSCLC Treatment in China
•
HutchMed (China) Ltd (HKG: 0013, NASDAQ: HCM) has announced that the China National Medical Products Administration (NMPA) has accepted and granted priority review to the New Drug Application (NDA) for its Orpathys (savolitinib). The Chinese company is seeking approval for its MET tyrosine kinase inhibitor (TKI), when combined with Tagrisso…
-
Innovent Biologics Strikes Licensing Deal with Roche for IBI3009 ADC
•
China-based Innovent Biologics, Inc. (HKG: 1801) has announced a significant licensing agreement with Swiss pharmaceutical giant Roche (SWX: ROG). The agreement grants Roche global exclusive development, manufacturing, and commercialization rights to Innovent’s IBI3009, a DLL3-targeted antibody drug conjugate (ADC) that is anticipated to offer new treatment options for patients with…
-
Maxvax Biotechnology Secures RMB 200 Million in Convertible Bonds Financing
•
Immunotherapy biotech company Maxvax Biotechnology, based in Chengdu, has announced the successful closure of a convertible bonds financing round, raising RMB 200 million (USD 27.4 million). The financing was subscribed to by the Shenzhen Capital Group Manufacturing Industry Transformation and Upgrading New Materials Fund, highlighting the investor’s confidence in Maxvax’s…
-
Zhaoke Ophthalmology’s TAB014 Achieves Positive Phase III Results for wAMD
•
China-based Lee’s Pharmaceutical Holdings Ltd’s (HKG: 0950) former subsidiary, Zhaoke Ophthalmology Ltd (HKG: 6622), has announced positive topline results from the Phase III study for its core candidate drug TAB014 in the treatment of wet (neovascularization) age-related macular degeneration (wAMD). The study successfully met all primary and key secondary endpoints,…
-
HutchMed to Divest 45% Stake in Shanghai Hutchison Pharmaceuticals for $608 Million
•
China-based HutchMed (China) Ltd (HKG: 0013, NASDAQ: HCM) has reached an agreement to divest its 45% equity interest in Shanghai Hutchison Pharmaceuticals Limited (SHPL) to GP Health Service Capital Co., Ltd and Shanghai Pharmaceuticals Holding Co., Ltd. (SPH, HKG: 2607, SHA: 601607) for a combined total of USD608 million. Background…
-
Boston Scientific Launches Athletis Peripheral Balloon Dilatation Catheter in China
•
US-based medical device leader Boston Scientific Corporation (NYSE: BSX) has announced the market launch of its Athletis peripheral balloon dilatation catheter in mainland China. This product is designed for percutaneous transluminal angioplasty (PTA) of the peripheral vascular system and is utilized in the treatment of stenotic lesions in autologous or…
-
Alphamab Oncology’s JSKN033 Advances to Phase III Trial for Platinum Resistant Ovarian Cancer
•
China-based Alphamab Oncology (HKG: 9966) has announced that it has received approval from the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) to proceed with a Phase III study for its drug candidate JSKN033. The study will compare JSKN033 against the investigator’s choice of chemotherapy in…
-
Frontera Therapeutics Advances to Phase II with FT-003 for Diabetic Macular Edema
•
Sino-US firm Frontera Therapeutics, Inc. has announced that it has received approval from the US Food and Drug Administration (FDA) to conduct a Phase II study assessing its recombinant adeno-associated virus (rAAV) gene therapy, FT-003, in patients with diabetic macular edema (DME). This follows previous clearance for a Phase II…
-
Johnson & Johnson’s Rybrevant Combo Approved by EC for First-Line NSCLC Treatment
•
US healthcare giant Johnson & Johnson (J&J, NYSE: JNJ) has announced that the European Commission (EC) has granted label extension approval for its Rybrevant (amivantamab) combined with Lazcluze (lazertinib) for the treatment of first-line advanced non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) exon 19 deletions…
-
BeiGene Secures Global Rights to Duality Biologics’ B7H4 Targeted ADC DB1312/BG-C9074
•
Duality Biologics, a developer of antibody conjugate drugs (ADCs) with operations in the United States and China, has announced that BeiGene Ltd. (HKG: 6160, SHA: 688235, NASDAQ: BGNE) has exercised its exclusive option to secure global development, manufacturing, and commercialization rights to Duality’s B7H4 targeted antibody-drug conjugate (ADC), DB1312/BG-C9074. Terms…
-
Novartis Announces Positive Results from Phase III STEER Study on SMA Treatment
•
Swiss pharmaceutical giant Novartis (NYSE: NVS) has announced positive topline results from the Phase III STEER study, which was designed to assess the efficacy and safety of its intrathecal onasemnogene abeparvovec (OAV101 IT) in treatment-naïve patients with spinal muscular atrophy (SMA) Type 2. The study focused on patients aged two…
-
Xtalpi Inc. Partners with Amazon Web Services to Accelerate Life Sciences Innovation
•
Shenzhen-based QuantumPharm Inc., operating under the name Xtalpi Inc. (HKG: 2228), has announced a strategic partnership with US-based Amazon Web Services (AWS). AWS will serve as Xtalpi’s cloud service provider, empowering the company to enhance its innovative development in life science, chemistry, and new materials through the use of artificial…
-
Jiangxi Jemincare Group Gets NMPA Approval for Prostate Cancer Drug JMX-2006
•
China-based Jiangxi Jemincare Group has announced that it has received clinical trial approval from the National Medical Products Administration (NMPA) to test its Category 2.2 modified drug, JMX-2006, in prostate cancer. JMX-2006: An Innovative Sustain-Released Preparation for Prostate CancerJMX-2006 is an innovative sustain-released preparation designed to offer less frequent dosages,…
-
CARsgen Therapeutics Initiates Trial for Universal CAR-T Therapy KJ-C2219 in China
•
China-based CARsgen Therapeutics Holdings Ltd (HKG: 2171) has announced the initiation of an investigator-initiated-trial (ITT) for its chimeric antigen receptor (CAR)-T therapy candidate product, KJ-C2219, in China. The trial is aimed at treating recurrent/refractory B-cell non-Hodgkin lymphoma (R/R B-NHL). KJ-C2219: A Universal CAR-T Therapy Targeting CD19 and CD20KJ-C2219 is a…
-
We Doctor Holdings Limited Files for IPO on Hong Kong Stock Exchange
•
China-based We Doctor Holdings Limited, a subsidiary of Chinese internet giant Tencent Corporate Venture Capital (HKG: 0700), has made an initial public offering (IPO) filing with the Hong Kong Stock Exchange. At this stage, no unit price or additional details have been disclosed. We Doctor’s AI-Based Healthcare SolutionsWe Doctor offers…
-
Shinva Medical Instrument to Acquire Stake in Wuhan Zhongzhi Biotechnologies for IVD Expansion
•
China’s Shinva Medical Instrument Co., Ltd (SHA: 600587) has announced its intention to acquire a significant stake in Wuhan Zhongzhi Biotechnologies Inc. (836834), purchasing 36.1913% of the company’s shares for RMB166.5 million (USD22.8 million). Zhongzhi Bio’s Focus on RNA Molecule IVD KitsFounded in 2011, Zhongzhi Bio is a company dedicated…
-
Hinova Pharmaceuticals’ HP568 Earns FDA Clinical Trial Approval for ER+/HER2- Breast Cancer
•
Chengdu-based biotech Hinova Pharmaceuticals Inc., (SHA: 688302) has announced that it has received clinical trial approval from the US Food and Drug Administration (FDA) for its drug candidate, HP568. The Chinese firm plans to test HP568 in patients with estrogen receptor (ER) positive, human epidermal growth factor receptor 2 negative…
-
CanSino Biologics’ Menhycia Receives Market Approval in Indonesia
•
China-based CanSino Biologics (HKG: 6185) has received market approval from the Badan Pengawas Obat dan Makanan (BPOM) of Indonesia for its ACYW135 Meningococcal Conjugate Vaccine (CRM197), commercially known as Menhycia. Menhycia: Protection for Infants and Young ChildrenMenhycia is indicated for infants and young children aged between 3 months to 3…
